This site uses tracking information. Visit our privacy policy. Click to agree to this policy and not see this again.

Ophthalmology and Visual Sciences

Behcet's Disease: A 32-year-old female with recurrent ocular inflammation

Behcet's Disease: A 32-year-old female with recurrent ocular inflammation

David L. Phillips, MD; James C. Folk, MD
Sept 29, 2014
Revised by Jason Kam, MD
Nov 28, 2016


Chief Complaint

Acute decrease in vision in the right eye without pain.

History of Present Illness

This 32-year-old female awoke in the morning with profound blurriness in the right eye (OD). She denies flashes, floaters, and pain in either eye.

She has also noted joint aches and pains which have been constant for the past several months as well as frequent headaches and neck pain. She is using 800 mg ibuprofen twice daily (BID) with partial relief of her headaches and joint pain. She also reports frequent painful oral ulcers she describes as "canker sores". She denies any past or present genital ulcers.

She recently had a skin biopsy by a dermatologist that showed pathology consistent with a panniculitis vs. erythema nodosum. An inflammatory work-up included a chest x-ray, Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complete blood count (CBC). The chest x-ray, ESR, and CRP were normal. The CBC showed a mildly elevated white blood count (WBC).

Review of Systems

She endorses persistent fatigue, headaches, dry eyes, sinusitis, dry mouth, oral ulcers, reflux, constipation, previous kidney stones, and infrequent menses.

She specifically denies genital ulcers or genital scars, fever, chills, night sweats, alopecia, photosensitivity, Raynaud's phenomena, red eyes, nasal ulcers, cough, dyspnea, hemoptysis, pleuritic chest pain, difficulty swallowing, nausea, vomiting, dysuria, renal disease, numbness, tingling, seizures, anxiety, and depression.

She has had a recent normal purified protein derivative (PPD) test for tuberculosis (TB) from her employer.

Past Ocular History

Her eyes were reportedly normal until she was approximately 25 years old. At that time she sustained a branch retinal vein occlusion (BRVO) in the left eye (OS). Approximately 5 years prior to this presentation, she was initially referred to University of Iowa Hospitals and Clinics (UIHC) for recalcitrant panuveitis in both eyes that was worse in the left eye. At that time, the work-up was negative for herpes simplex (HSV), varicella zoster, and cytomegalovirus (CMV) via polymerase chain reaction (PCR) testing of an anterior chamber (AC) tap and serologies showed a negative rapid plasma reagin (RPR) for syphilis. The ocular inflammation was controlled with oral and topical corticosteroids. Cyclophosphamide was started, but discontinued due to poor tolerance by the patient. With taper of the steroids, the left eye had a flare of inflammation requiring a Retisert® (fluocinolone acetonide) implant that successfully quieted the eye. Following the Retisert implant, a cataract developed in the left eye that was subsequently removed with placement of an intraocular lens (IOL) without complication. Intraocular pressure remained elevated in the left eye and was resistant to medical therapy, necessitating a glaucoma drainage device implantation several months later. Following the withdrawal of oral steroids, the right eye developed persistent inflammation and cystoid macular edema (CME). A 0.7 mg Ozurdex® (dexamethasone) injection was given with partial improvement of the inflammation. Approximately, two years prior her most recent presentation, the right eye struggled with persistent inflammation resistant to topical steroid therapy. Subsequently, vision decreased due to persistent CME, cataract, and persistent anterior vitreous cells. She then underwent cataract extraction with concomitant intra-ocular lens insertion, glaucoma drainage device implantation, and Retisert (fluocinolone acetonide) implantation. This eye had been doing well until this recent presentation.

Past Medical History

  • Migraines
  • Psoriasis
  • Uncomplicated pregnancy
  • Mild anemia
  • No other known autoimmune disease

Topical Ocular Medications

  • Combigan® (brimonidine/timolol) drops in the left eye (OS) BID

Oral Medications

  • None


  • Penicillin

Family History

  • Psoriasis
  • No other known autoimmune diseases

Social History

  • She is a current smoker at one pack per day, rarely consumes alcohol, and works within a correctional facility.


  • Thin, well-appearing female in no acute distress


Current Spectacle Correction

  • OD: -1.25 diopters (D) sphere
  • OS: -1.00 D sphere

Visual Acuity with correction (Snellen)

  • OD: Count fingers at 5 feet (was 20/20 two months prior)
  • OS: 20/40 with no improvement on pin hole (20/40 baseline vision since 2010)

Extraocular Motility

  • Full OU


  • OD: 4 mm (dark) → 2 mm (light) with no relative afferent pupillary defect (RAPD)
  • OS: 4 mm (dark) → 3mm (light) with a 1.8 log unit RAPD

Intraocular Pressure

  • OD: 10 mmHg
  • OS: 10 mmHg

Anterior Segment Examination

  • OD:
    • Conjunctiva/Sclera: Superotemporal glaucoma drainage device covered a cornea patch graft and conjunctiva
    • Cornea: Clear
    • AC: Deep free of cell or flare, Superotemporal tube shunt
    • Iris: Normal
    • Lens: Posterior chamber IOL in place with mild posterior capsular opacification
  • OS:
    • Conjunctiva/sclera: Superotemporal glaucoma drainage device covered with corneal patch graft and conjunctiva
    • Cornea: Clear
    • AC: Deep free of cell or flare, superotemporal tube shunt
    • Iris: normal
    • Lens: Posterior chamber IOL in place with open posterior capsule

Dilated Fundus Examination

  • OD:
    • Vitreous: 1+ anterior vitreous cells that appear white and refractile
    • Optic Nerve: Normal
    • Macula: Macular edema is present
    • Vessels: Attenuation of the arteries with possible engorgement of the veins especially near the disc
    • Periphery: Normal
  • OS:
    • Vitreous: clear
    • Optic Nerve: Cupped
    • Macula: No CME, trace epiretinal membrane (ERM)
    • Vessels: Mild vessel tortuosity
    • Periphery: Normal with a Retisert inferiorly
Figure 1: Color fundus photography
Right Eye (OD) Left Eye (OS)
Color Fundus, right eye Color Fundus, left eye
Mild vitreous cells causing haze, moderate optic nerve inflammation, and focal narrowing of the retinal arterioles. A serous elevation of the macula, inferior flame-shape hemorrhages through the posterior pole, and a large cotton wool spot just off the disc. Stable tortuous vessels, cupping of the optic nerve, inferior venous tortuosity and a faint epiretinal membrane over the macula.
Figure 2: Goldmann visual field (1yr prior to recent presentation)
Right Eye (OD) Left Eye (OS)
G V F Essentially full and stable Dense superior and inferior constriction, but overall stable
Essentially full and stable Dense superior and inferior constriction, but overall stable
Figure 3A: Fluorescein angiogram, right eye (OD)
erivenular phlebitis is noted in mid frames Small punctate areas of early hypofluorescence in the peri-foveal region in the area of the cotton wool spot just supratemporal to disc.
erivenular phlebitis is noted in mid frames Late hyperfluorescence and leakage around the disc in area of cotton wool spot.
Small punctate areas of early hypofluorescence in the peri-foveal region in the area of the cotton wool spot just supratemporal to disc. Perivenular phlebitis is noted in mid frames.  Late hyperfluorescence and leakage around the disc in area of cotton wool spot.  
Figure 3B: Fluorescein angiogram, left eye (OS)
Late leakage from the infero-temporal venous vasculature with mild inferior peripheral periphlebitis with late hyperfluorescence. Late leakage from the infero-temporal venous vasculature with mild inferior peripheral periphlebitis with late hyperfluorescence.
Late leakage from the infero-temporal venous vasculature with mild inferior peripheral periphlebitis with late hyperfluorescence.
Figure 4: Montage of late fluorescein angiogram
Figure 5:  Spectralis OCT at the time of recent presentation
Central macular thickness is 819 microns (320 microns prior) there is a large, foveal-involving, serous retinal detachment. Central macular thickness is 267 (266 microns prior) there is an ERM slight outer retinal segment derangement
Central macular thickness is 819 microns (320 microns prior) there is a large, foveal-involving, serous retinal detachment. Central macular thickness is 267 (266 microns prior) there is an ERM slight outer retinal segment derangement

Clinical Course


The diagnosis of Behcet's disease was made fulfilling the requirements set forth from the international study group for Behcet's disease (see below).

Oral prednisone was started at 60mg a daily with notable improvement in 48 hours.

An urgent rheumatology consult was obtained the same day with the laboratory work-up obtained below. Rheumatology started azathioprine 50mg by mouth daily with plans to increase it to 125mg daily, which they believed was the maximum safe dose according to her weight.                   

Laboratory work-up

  • Kidney: Function Normal
  • Urine analysis: Normal
  • Liver Function: Normal
  • Hepatitis panel: Negative
  • CBC/Electrolytes: Normal
  • Angiotensin-Converting Enzyme (ACE) level: normal
  • Complement 3 and Complement 4 levels: Normal
  • Antinuclear Antibody (ANA): <1:80
  • Double Stranded DNA Antibody: Negative
  • Anti-Ro (SS-A) and Anti-La (SS-B) Antibody: Negative
  • Anti-neutrophil Cytoplasmic Antibody (ANCA): Negative
  • Anti-cyclic Citrullinated Peptide (CCP): Negative
  • Quantiferon-Gold for TB: Negative
  • ESR/CRP: Normal

Follow-up Course

Initially the patient did very well with improved vision, but was unable to tolerate the insomnia and the effect that prednisone had on her mood. Thus, the oral prednisone was tapered and the titration of the azathioprine commenced. Unfortunately, with the taper of the steroids her symptoms and inflammation returned. The decision was made to increase back to 60 mg of oral prednisone. Her side effects with regards to mood, behavior, and insomnia severely worsened after the increase. A discussion with rheumatology was held and it was felt that her best option was implementing Humira® (adalimumab) while switching from azathioprine to mycophenolate mofetil, and starting a rapid steroid taper. With the addition of adalimumab her ocular inflammation was rapidly controlled. Nearly 12 months later, her ocular inflammation is controlled with adalimumab injection every 2 weeks and 1000mg BID of mycophenolate mofetil. The prednisone was successfully tapered to 7.5mg per day. A yttrium aluminum garnet (YAG) capsulotomy was performed in the right eye resulting in 20/20 vision. Her left eye remains quiet with 20/40 vision and a constricted field due to glaucoma. There are plans to further taper her prednisone.

Figure 6: Color fundus photography, 3 months following initiating treatment
Epiretinal membrane with retinal thickening at the macula, attenuation of the retinal vasculature with resolution of the vasculitis and fluid in the macula. Stable tortuous optociliary shunt vessels in the cup of the disc, mild epiretinal membrane.
Epiretinal membrane with retinal thickening at the macula, attenuation of the retinal vasculature with resolution of the vasculitis and fluid in the macula.
Stable tortuous optociliary shunt vessels in the cup of the disc, mild epiretinal membrane.
Figure 7: Spectralis OCT, 3 months following initiating treatment
mild ERM; no cystoid macular edema (CME) or sub-retinal fluid (SRF) mild ERM; no CME or SRF 
mild ERM; no cystoid macular edema (CME) or sub-retinal fluid (SRF) mild ERM; no CME or SRF 


Behçet's Disease (BD) is a rare, idiopathic, chronic, relapsing, occlusive vasculitis involving arteries and veins of all caliber. As a result, it causes various ocular and systemic manifestations. The first report of this disease was made in 1931 by Greek ophthalmologist, Adamantiades, who described a patient with recurrent iritis, hypopyon, phlebitis, mouth ulcers, genital ulcers, and knee arthritis [1]. Hulusi Behçet's, a dermatologist, described three patients with the classic triad of "oral and genital ulcers with recurrent iritis" in 1937 [2]. Thus, some texts refer to this condition as Adamantiades-Behçet's disease.

The Silk Road

Figure 8: Silk Road. Adapted from Public Domain, NASA/Goddard Space Flight Center derivative work, from Wikipedia: Silk Road:

BD is recognized worldwide. However, its prevalence is greatest in the northern hemisphere, especially in eastern Mediterranean countries and eastern Asia along the ancient Silk Road. Above is a map of the silk trade routes illustrating some of the common areas affected by BD. Turkey has the highest prevalence. Azizlerli et al. [3] from Istanbul reported prevalence to be nearly 1/250 in a population greater than 11 years old. In Japan, BD is responsible for 11–20% of blindness acquired before middle age [4]. BD is rare in Western countries; prevalence has been found to be 0.64/100,000 in the United Kingdom and 0.12–0.33/100,000 in the United States of America.


BD typically presents between the ages of 25-40, with children rarely affected. Studies show no significant gender predilection for BD [5]. Familial BD has been reported in 1-18% of patients; thus, the majority of BD cases are sporadic [6,7]. The criteria for diagnosis varies depending on which classification scheme is used, which reflects the imperfect nature of diagnosing BD (discussed later). Unfortunately, BD remains a clinical diagnosis with no confirmatory laboratory test [7].

The pathophysiology remains unknown, however several theories have been proposed. One theory postulates an infectious component of either herpes simplex virus, hepatitis C, or Streptococcus Sanguis (oral flora) [8]. Other theories propose an autoimmune phenomenon with HLA-B51 implicated in association with BD in several genome-wide association studies [8].


Ocular involvement can be quite variable; however ocular involvement is observed in 70% of BD patients at some point during the disease course. Ocular signs and symptoms are bilateral in 80% and can involve the anterior and/or posterior segments [9]. Photophobia is the primary symptom for anterior segment inflammation, whereas posterior segment inflammation typically presents with floaters and visual loss. Ocular involvement is typically a non-granulomatous inflammation with or without a necrotizing occlusive vasculitis, which can be explosive in nature. When anterior uveitis is present, it is classically taught that a shifting hypopyon will be present, but this is only true in a third of cases [9-12]. Anterior uveitis can lead to posterior synechiae, iris bombe, and angle closure. Posterior uveitis in BD can ultimately lead to blindness, thus warranting prompt attention and treatment. In the acute stage, arterial and venous vasculitis, acute periphlebitis and thromboangiitis, CME, and ischemia-induced neovascularization of the retina and optic disc can all be observed. Phlebitis (venous vasculitis) is generally the predominant form of vasculitis, but arteritis has been documented [10]. Chronically sclerotic and deranged retinal vessels can be observed in end-stage disease. Approximately 5% of patients develop neovascular glaucoma [5,12].

Systemic manifestations

Mucous membranes

Recurrent aphthous ulcers, the primary finding in BD, start as painful papules in the oral cavity that rapidly become ulcerated with a pseudomembrane [9,12,13]. They are often numerous and occur frequently. Aphthous ulcers are found in almost 100% of patients with BD. Genital ulcers are often found on the scrotum and inguinal area in men and on the vulva in women [9,12,13]. Ulcers can also affect the tongue, lips, gingiva, tonsils, uvula, palate, or pharynx.


Erythema nodosum (EN) is an inflammatory skin condition characterized by red, tender nodules, usually occurring on the legs and ankles. It can also appear on the face, neck, or arms. EN is also associated with other diseases, and these lesions typically heal without scars. EN lesions associated with BD frequently ulcerate [5,13]. Other skin lesions such as folliculitis and acneiform pustules are also common.


Aneurysms (outpouchings of blood vessel walls, caused by inflammation) of arteries in the lung may rupture and may lead to massive lung hemorrhages. Papers report anywhere from 5 to 50% of these processes occurring. Systemic vasculitis may also occur in 25% of patients with any size artery or vein in the body involved [5]


Endocarditis, myocarditis and fibrosis, coronary arteritis, and pericarditis can have a prevalence as high as 17% [5].


The lining of the gastrointestinal system, including the esophagus, stomach, and intestines, can develop ulcers [14]. Epididymitis is also commonly seen in patients with BD.


Pulmonary involvement is mainly pulmonary arteritis with aneurysmal dilation of the pulmonary artery [12].

Neurologic (neuro-Behçet's)

Central nervous system involvement is one of the most dangerous manifestations of BD. BD  involvement of the white matter portion of the brain and brainstem can lead to headaches, confusion, strokes, cranial nerve palsy, motor problems, personality changes, and rarely, dementia. BD may also involve the meninges, leading to meningitis ("aseptic" meningitis). Ten percent of patients with neuro-Behçet's have ocular findings, and 30% of ocular BD patients have brain involvement. Mortality is reported to be as high as 10% in patient with neurologic involvement, with men affected more often than women [5, 16]. Central nervous system involvement can be particularly debilitating for patients and warrants aggressive therapy.


Arthritis is observed in 10-15% of patients. This arthritis is non-destructive, and the knees are the most often affected [5, 12].


Currently there are two published diagnostic criteria (table 1, table 2).

Table 1. Information from the Behçet's Disease Research Committee of Japan [18]

Major Criteria

  • Recurrent oral aphthous ulcers
  • Skin lesion (erythema nodosum, acneiform pustules, folliculitis)
  • Recurrent genital ulcers
  • Ocular inflammatory disease

Minor Criteria

  • Arthritis
  • Gastrointestinal ulceration
  • Epididymitis

Types of Behçet's disease

  • Complete (4 major criteria)
  • Incomplete (3 major criteria or ocular involvement with 1 other major criterion)
  • Suspect (2 major criteria with no ocular involvement)
  • Possible (1 major criterion)

Table 2. Information from the International Criteria of Behçet's Disease: total score  ≥ 4 indicates a diagnosis of BD [18]. This was published previously in 1990 by the International study group for Behçet's [19] and was updated in 2014 [18].



Ocular lesions


Genital aphthosis


Oral aphthosis


Skin lesions


Neurological manifestations


Vascular manifestations


Positive pathergy test*


  • *Pathergy test is optional and the primary scoring system does not include pathergy testing. However, when pathergy testing is conducted, one extra point may be assigned for a positive result.


HLA testing

In BD, HLA-B12 has been associated with mucocutaneous lesions [7]. HLA-B51 is associated with ocular lesions. Many people from the Middle East and Asia have HLA-B51 [40-70%) while only 13% of European and North Americans have HLA-B51 [5, 7]. Patients with HLA-51 have a six-fold increased risk of BD and typically have more manifestations of the disease. Thus, HLA-testing has little diagnostic value and is typically not performed. Again, BD is a clinical diagnosis.

A positive pathergy test can be supportive of the diagnosis of BD, but it is not diagnostic alone. A pathergy test is a simple test in which the forearm is pricked with a small, sterile needle. Occurrence of a small red bump or pustule at the site of needle insertion constitutes a positive test. Though a positive pathergy test is helpful in the diagnosis of BD, only a minority of patients demonstrate the pathergy phenomenon. Patients from the Mediterranean region are more likely to demonstrate pathergy. Other conditions can occasionally result in a positive pathergy test. Hence, the pathergy test is not specific and is rarely tested in the United States.  However, part of the diagnostic criteria for the International Criteria of Behçet's Disease includes the pathergy test [18].


The treatment mantra is generally long-term control with systemic immunosuppressives, such as steroid-sparing agents. The most widely accepted of these was created in 2008 by the European League Against Rheumatism (EULAR). Aggressive immunotherapy is usually instituted in young males or those with neurologic or retinal involvement [5, 13, 14, 16]. Corticosteroids are initially used to control acute inflammation, but they are a poor long-term option as resistance can develop and side effects may become severe [5, 16, 20-22]. Previously, experts recommended starting azathioprine or cyclosporine in patients with posterior segment involvement. Cyclosporine is generally used in more severe disease [20,21]. Cyclosporine may accelerate neurological symptoms or have neurotoxicity, so monitoring for new neurologic symptoms is necessary. Colchicine, cyclophosphamide, dapsone, and thalidomide have also been used with varying success and side-effect profiles [20,21].

Biologic agents are gaining acceptance in the treatment of BD. Biologic agents are used to inhibit cytokine signaling, such as tumor necrosis factor (TNF)-alpha (infliximab, adalimumab), as well as lymphocyte-targeted therapies, such as anti-CD20 (rituximab). Infliximab has been shown to be efficacious in several retrospective studies in controlling refractory eye disease [20]. In a retrospective study from a French registry that included 124 patients, the efficacy of TNF inhibition for BD was confirmed [22]. Expert panel recommendations for ocular manifestations of BD now include treatment with anti-TNF therapy with infliximab or adalimumab. This may be considered as first or second-line corticosteroid-sparing therapy. Etanercept may be considered if both infliximab and adalimumab are poorly tolerated [23].


There is no cure for BD. The most prevalent morbidity is ocular disease. Approximately 25% of patients with chronic ocular involvement have 20/200 vision or less due to macular edema, vasculitis, retinal detachment, vitreous hemorrhage, neovascularization, atrophy of the optic nerve, or glaucoma [5,20,21]. Even with treatment, up to 75% of patients lose useful vision after a 6-10 year period following the onset of ocular symptoms [5, 21].

BD may be fatal, with a mortality rate of up to 6%. Death occurs from vasculitis leading to arterial occlusion, ruptured arterial aneurysms, pulmonary vasculitis, or involvement of the central nervous system [5].

Epidemiology of Behcet's

  • Onset typically 20-30 years old
  • Men = women
  • Increased frequency in those of Middle Eastern or Japanese descent
  • Association with HLA-B51 (but not diagnostic)

Signs of Behcet's

  • Anterior ocular inflammation (shifting hypopyon)
  • Posterior inflammation with venous and arterial vasculitis (possibly obliterative)
  • Positive pathergy test
  • Aphthous ulcers
  • Genital ulcers
  • Erythema nodosum
  • Dermatographia

Symptoms of Behcet's

  • Photophobia
  • Vision loss
  • Oral ulcers
  • Genital ulcers
  • Arthritis
  • Headache
  • Skin ulceration or nodules

Management of Behcet's

  • Acute management with topical and systemic corticosteroids
  • Urgent referral to rheumatology
  • First/second line treatment with steroid sparing immunomodulation with infliximab or adalimumab

Differential Diagnosis

  • HLA-B27-associated uveitis (often unilateral with a less mobile hypopyon)
  • Reactive arthritis
  • Sarcoidosis
  • Systemic lupus erythematosus
  • Polyarteritis nodosa
  • Wegener's granulomatosis
  • Acute retinal necrosis
  1. Adamantiades B. Sur un cas d'iritis à hypopion récidivant. Ann Ocul (Paris)1931;168:271-278.
  2. H. Behçet. Über rezidivierende aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und am den Genitalien. Dermatologische Wochenschrift, Hamburg. 1937;105:1152-1157.
  3. Azizlerli G, Köse AA, Sarica R, Gül A, Tutkun IT, Kulaç M, et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803–6.
  4. Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K. The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçt's disease in Japan: Ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;77:225–79.
  5. Alpsoy E. Behçet's 's disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43[6]:620-632.
  6. Ucar-Comlekoglu D, Fox A, Hida San H. Gender Differences in Behçet;'s Disease Associated Uveitis. J of Ophthalmol. 2014:820710.
  7. De Menthon M, LaValley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Care and Research. 2009;61[10]:1287–1296. 
  8. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet's disease. Autoimmunity Reviews. 2012;11[10]:687–698. [
  9. Foster SC, and Vitale AT. Diagnosis and Treatment of Uveitis. New Delhi: Jaypee Highlights, 2002; Chapter 56, p 632-653.
  10. Nussenblatt RB, and Whitcup SM, Uveitis: Fundamentals and Clinical Practice 4th ed. 2010; Chapter 26, p 332-354.
  11. Joussen AM, Gardner TW, Kirchhof B, and Ryan SJ. Retinal Vascular Disease. Berlin: Springer, 2007. Chapter 25.3, p 635-645.
  12. Davatchi F, Chams-Davatchi C, Shams H, et al. Adult Behçet's disease in Iran: analysis of 6075 patients. Int J Rheum Dis 2016; 19:95–103.
  13. Tugal-Tutkun I, Gupta V, Cunningham ET. Differential diagnosis of Behçet's  uveitis. Ocul Immunol Inflamm. 2013;21[5]:337-350.
  14. Vaiopoulos AG, Sfikakis PP, Kanakis MA, Vaiopoulos G, Kaklamanis PG. Gastrointestinal manifestations of Behçet's disease: advances in evaluation and management. Clin Exp Rheumatol.2014;32:S140–S148. 
  15. Lightman S, Towler. Fundamentals of clinical ophthalmology: Uveitis. London: BMJ Books, 1998. Chapter 6, p. 87-100
  16. Marta M, Santos E, Coutinho E, et al. The role of infections in Behçet's  disease and neuro-Behçet's  syndrome. Autoimmun Rev. 2015;14[7]:609-615.
  17. Behçet's 's Disease Research Committee of Japan. Behçet's 's disease guide to the diagnosis of Behçet's 's disease [1972] Japanese Journal of Ophthalmology. 1974;18:291–4.
  18. International Team for the Revision of the International Criteria for Behçet's 's D. The International Criteria for Behçet's 's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28[3]:338-347.
  19. Criteria for diagnosis of Behçet's disease. International study group for Behçet's disease. Lancet.1990;335:1078–80. 
  20. Fresko I and Yzici H. Treatment strategies for Behçet's Disease. Expert Opin Pharmacother. 2008;9[18]:3211-3219. [PMID 19040341]
  21. Benezra D, and Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986;70[8]:589-592. [PMID 3741823]
  22. Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: multicenter study of 124 patients. J Autoimmun 2015; 62:67-74. [PMID 26162757]
  23. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121[3]:785-796 e783. [24359625]
Suggested citation format:

Kam J. Revision of [Phillips DL, Folk JC. Behcet's Disease: A 32-year-old female with recurrent ocular inflammation. Sept 29, 2014.] November 28, 2016; Available from:

last updated: posted 9/29/2014; revised 11/28/2016

Image Permissions:
Creative Commons

Ophthalmic Atlas Images by, The University of Iowa are licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.